Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 8/2007

01-08-2007 | Commentary

Considerations in Drug Handling in Renal Disease

Author: Domenic A. Sica

Published in: Clinical Pharmacokinetics | Issue 8/2007

Login to get access

Excerpt

The incidence of chronic kidney disease (CKD) is on the upswing in most industrialised countries. The protean nature of CKD-related diseases is such that wide arrays of healthcare providers are now routinely called on to assist in the management of these patients. Quite logically, this level of attention exposes CKD patients to diverse therapies, many of which are pharmacological in nature; thus, the interplay between CKD and the dosing of various drug therapies becomes an important treatment consideration that requires continuous vigilance.[1] …
Literature
1.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl. 1): S1–S266
2.
Sica DA. Kinetics of angiotensin converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992; 20 Suppl. 10: S13–20PubMed
3.
Frishman WH, Alwarshetty M. β-adrenergic blockers in systemic hypertension. Clin Pharmacokinet 2002; 41: 505–16PubMedCrossRef
4.
5.
Sica DA. Hypertension, renal disease, and drug considerations. J Clin Hypertens (Greenwich) 2004; 6: 24–30CrossRef
6.
Vaidyanathan S, Bigler H, Yeh CM, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46(8): 661–75PubMedCrossRef
7.
US FDA Center for Drug Evaluation and Research. Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling [online]. Rockville (MD): Center for Drug Evaluation and Research, 1998. Available from URL: http://​www.​fda.​gov/​cder/​guidance/​1449fnl.​pdf [Accessed 2007 Jun 26]
8.
Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001; 10: 785–92PubMedCrossRef
Metadata
Title
Considerations in Drug Handling in Renal Disease
Author
Domenic A. Sica
Publication date
01-08-2007
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 8/2007
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200746080-00004

Other articles of this Issue 8/2007

Clinical Pharmacokinetics 8/2007 Go to the issue

Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol

Original Research Article

Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris

Review Article

Clinical Pharmacokinetics and Use of Infliximab

Original Research Article

General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs

Original Research Article

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren Alone and in Combination with Irbesartan in Renal Impairment